R&D
Aprea Doubles Down on Its Cancer Drug After Early Responses in Hard-to-Treat Tumors
The WEE1 inhibitor APR-1051 shrank tumors in some patients with gynecologic cancers in an early trial, prompting Aprea to expand testing.